

Evaluation of Patients with COVID-19 Followed Up in Intensive Care Units in the Second Year of the Pandemic: A Multicenter Point Prevalence Study

Sinem Güngör¹, Özlem Ediboğlu², Özlem Yazıcıoğlu Moçin¹, Nalan Adıgüzel¹, Eylem Tunçay³, İnşa Gül Ekiz İşcanlı¹, Berrin Er⁴, Zuhal Karakurt¹, Sema Turan⁴, Behiye Deniz Kosovalı⁵, Nevzat Mehmet Mutlu⁶, Duygu Kayar⁴, Şerife Gökbülüt Bektaş⁷, Elmas Uysal⁴, Fatih Seğmen⁴, Gürayalp Alp⁸, Deniz Erdem⁸, Nazan Has Selmi⁴, Pınar Güven⁹, Zerrin Özçelik⁹, Merve Ocakcıoğlu³, Canan Yazıcı Özgür¹⁰, Rabia Yılmaz¹¹, Deniz Bilgi Özel¹², Halil Cebeci¹², Bahar Güler¹¹, Canan Cansever¹³, Mehmet Cakırca¹⁴, Hansa İnceöz¹⁵, İlker Solmaz¹⁵, Fatma Özkan Sipahioğlu¹⁶, Eda Macit Aydın¹⁶, Hakan Dayanır¹⁷, Sait Fatih Öner¹⁸, Umut Karatepe¹⁸, Serkan Özen¹⁸, Maruf Boran¹⁹, Dursun Fırat Ergül¹⁹, Umut Sabri Kasapoğlu²⁰, Leman Acun Delen²¹, Erol Toy²², Koray Altun²³, Tuna Albayrak²⁴, Hülya Yanal²⁵, Gizem Zaim²⁶, Volkan Yazar²⁷, Gökhan Kılınç²⁷, Mustafa Deniz²⁸, Esra Özdemir²⁹, Veysel Garani Soylu³⁰, Ayşe Yılmaz³¹, Saba Mukaddes Saygılı², Ejder Kamil Öztürk³², Begüm Ergan³², Selin Eyüpoğlu³³, Yiğit Şahin³⁴, Beyza Yüksel³³, Azime Bulut³³, Aykut Sarıtaş³⁵, Hicret Yeniyay³⁵, Mürşide Genç³⁶, Feyza Kargin³⁷, Osman Özcan³⁸, Ebru Karakoç³⁸, Umran Karaca³⁹, Didem Sözütek⁴⁰, Sema Sarı⁴¹, Nimet Şenoğlu⁴², Hakan Ayyün⁴², Arzu Ceren Yiğit⁴³, Nilgün Kavruk⁴⁴, Çağdaş Alp Uzan⁴⁵, Murat Bıçakcıoğlu⁴⁶, Serkan Solak⁴⁷, Hatice Kutbay Özçelik⁴⁸, Kamuran Uluç⁴⁹, İlker Yıldırım⁵⁰, Makbule Cavidan Arar⁵⁰, İsmail Demirel⁵¹, Soner Umut Küver⁵², Eylem Sercan Özgür⁵³, Kutlay Aydın⁵⁴, Gül Erdal Dönmez⁵⁵, Gülbin Aygencel⁵⁶, Aliye Esmoğlu⁵⁷, Berrak Sebil Aydın⁵⁸, Murat Emre Tokur⁵⁹, Pervin Korkmaz Ekren⁶⁰, Yusuf Aydemir⁶¹, Başak Çakır Güney⁶², Ömer Yavuz Erdil⁶³, Abdurrahman Tüney⁶⁴, Türkan Bahadır⁶⁵, Serkan Uçkun⁶⁶, Nazan Kocaoğlu⁶⁶, Hüseyin Ulaş Pınar⁶⁷, Nurcan Kutluer Karaca⁶⁸, Hamza Gültekin⁶⁹, Pınar Ayyat⁷⁰, Ayşe Belin Özer⁷¹, Ahmet Eroğlu⁷², Ufuk Kuyruklu Yıldız⁷³, Çağdaş Baytar⁷⁴, Hilal Ayoğlu⁷⁴, Serpil Mızrakçı⁷⁵, Hatice Metin⁷⁶, Özgecan Pırl Zambak Mutlu⁷⁷, Hakan Yılmaz⁷⁸, Filiz Tüzüner⁷⁸

¹Department of Respiratory Intensive Care, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

²Department of Intensive Care Unit, University of Health Sciences İzmir Dr. Suat Şeren Chest Diseases and Thoracic Surgery Training and Research Hospital, Izmir, Turkey

³Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey

⁴Medical Intensive Care Unit, Ankara City Hospital, Ankara, Turkey

⁵Department of Critical Care, Ankara Bilkent City Hospital, Ankara, Turkey

⁶Department of Critical Care, University of Health Sciences Ankara City Hospital, Ankara, Turkey

⁷Department of Intensive Care, Ankara Bilkent City Hospital, Ankara, Turkey

⁸Department of Intensive Care, University of Health Sciences Ankara City Hospital, Ankara, Turkey

⁹Department of Intensive Care, Prof. Dr. Feriha Öz Emergency and Pandemic Hospital, İstanbul, Turkey

¹⁰İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

¹¹Department of Intensive Care, University of Health Sciences Bakırköy Sadi Konuk Training and Research Hospital, İstanbul, Turkey

¹²University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey

¹³University of Health Sciences Ankara City Hospital, Ankara, Turkey

¹⁴Ankara Training and Research Hospital, Ankara, Turkey

¹⁵University of Health Sciences Gülhane Training and Research Hospital, İstanbul, Turkey

¹⁶Department of Intensive Care, Clinic of Anesthesiology and Reanimation, Ankara Etlik City Hospital, Ankara, Turkey

¹⁷University of Health Sciences Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

¹⁸Elazığ Fethi Sekin City Hospital, Elazığ, Turkey

¹⁹Department of General Intensive Care Unit, Amasya University Sabuncuoğlu Şerafettin Training and Research Hospital, Amasya, Turkey

²⁰Department of Intensive Care, Marmara University Faculty of Medicine, İstanbul, Turkey

²¹Department of Anesthesiology and Reanimation, Malatya Training and Research Hospital, Malatya, Turkey

²²Karabük Training and Research Hospital, Karabük, Turkey

²³Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey

²⁴Giresun Faculty of Medicine, Giresun, Turkey

²⁵Department of Anesthesiology and Reanimation, İlhan Özdemir Public Hospital, Giresun, Turkey

²⁶Giresun Prof. Dr. A. İlhan Özdemir Public Hospital, Giresun, Turkey

²⁷Balıkesir Atatürk City Hospital, Balıkesir, Turkey

²⁸Department of Intensive Care, İzzet Baysal State Hospital, Bolu, Turkey

²⁹Bolu İzzet Baysal Public Hospital, Bolu, Turkey

³⁰Department of General Intensive Care, Kastamonu University, Kastamonu, Turkey

³¹Kastamonu Training and Research Hospital, Kastamonu, Turkey

³²Department of Intensive Care, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey

³³Giresun Training and Research Hospital, Giresun, Turkey

³⁴Giresun University Training and Research Hospital, Giresun, Turkey

³⁵Department of Intensive Care Unit, University of Health Sciences İzmir Tepecik Training and Research Hospital, İzmir, Turkey

³⁶University of Health Sciences Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Turkey

³⁷Department of Intensive Care, University of Health Sciences Kartal Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey

³⁸Department of Anesthesiology and Reanimation, Eskişehir Osmangazi University, Eskişehir, Turkey

³⁹University of Health Sciences Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

⁴⁰Department of Intensive Care, University of Health Sciences Adana City Hospital, Adana, Turkey

Corresponding author: Sinem Güngör, e-mail: sinematikungor@yahoo.com



- ⁴¹Niğde Training and Research Hospital, Çankaya, Turkey
⁴²Bakırçay University Çiğli Training and Research Hospital, İzmir, Turkey
⁴³Tokat Public Hospital, Tokat, Turkey
⁴⁴Department of Anesthesiology and Reanimation, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey
⁴⁵Ordu Public Hospital, Ordu, Turkey
⁴⁶Department of Anaesthesiology and Reanimation, İnönü University Faculty of Medicine, Malatya, Turkey
⁴⁷Ankara Etlik City Hospital, Ankara, Turkey
⁴⁸University of Health Sciences Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, İstanbul, Turkey
⁴⁹Department of Anesthesiology and Reanimation, University of Health Sciences Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey
⁵⁰Tekirdağ Namık Kemal University Hospital, Tekirdağ, Turkey
⁵¹Firat University Faculty of Medicine, Elazığ, Turkey
⁵²Başakşehir Çam and Sakura Hospital, İstanbul, Turkey
⁵³Department of Chest Diseases, Mersin University Faculty of Medicine, Mersin, Turkey
⁵⁴Aydın Public Hospital, Aydın, Turkey
⁵⁵University of Health Sciences Süreyyapaşa Chest Disease and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey
⁵⁶Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
⁵⁷Department of Anesthesiology and Reanimation, Erciyes University Faculty of Medicine, Kayseri, Turkey
⁵⁸Department of Anesthesiology and Reanimation, Karadeniz Ereğli Public Hospital, Ereğli, Turkey
⁵⁹Ege University Faculty of Medicine, İzmir, Turkey
⁶⁰Department of Pulmonary Disease, Ege University Faculty of Medicine, İzmir, Turkey
⁶¹Sakarya University Faculty of Medicine, Sakarya, Turkey
⁶²University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey
⁶³Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey
⁶⁴University of Health Sciences İstanbul Training and Research Hospital, İstanbul, Turkey
⁶⁵Beyşehir Public Hospital, Konya, Turkey
⁶⁶Department of Anaesthesiology and Reanimation, Balıkesir University Faculty of Medicine, Balıkesir, Turkey
⁶⁷Department of Anaesthesiology and Reanimation, KTO Karatay University Faculty of Medicine, Konya, Turkey
⁶⁸Department of Anaesthesiology and Reanimation, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey
⁶⁹Dicle University Faculty of Medicine, Diyarbakır, Turkey
⁷⁰İzmir Democracy University Faculty of Medicine, İzmir, Turkey
⁷¹Department of Anesthesiology and Reanimation, İnönü University Faculty of Medicine, Malatya, Turkey
⁷²Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
⁷³Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey
⁷⁴Department of Anaesthesiology and Reanimation, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
⁷⁵Mersin Liv Hospital, Mersin, Turkey
⁷⁶Erciyes University Faculty of Medicine, Kayseri, Turkey
⁷⁷Bahçelievler State Hospital, İstanbul, Turkey
⁷⁸Department of Anesthesiology and Reanimation, Ufuk University Faculty of Medicine, Ankara, Turkey

Cite this article as: Güngör S, Ediboğlu Ö, Yazıcıoğlu Moçin Ö, et al. Evaluation of patients with COVID-19 followed-up in intensive care units in the second year of the pandemic: A multicenter point prevalence study. Thorac Res Pract. 2023. [epub ahead of print]

Abstract

OBJECTIVE: A 1-day point prevalence study was planned to obtain country data by determining the clinical characteristics, follow-up and treatment methods of coronavirus disease 2019 (COVID-19) cases that required intensive care unit (ICU) treatment in the second year of the pandemic.

MATERIAL AND METHODS: All patients who were hospitalized in the ICUs due to COVID-19 between March 11, 2022, 08.00 AM, and March 12, 2022, 08.00 AM, were included in the study. Demographic characteristics, intensive care and laboratory data, radiological characteristics, and follow-up results of the patients were recorded.

RESULTS: A total of 811 patients from 59 centers were included in the study, 59% of the cases were male, and the mean age was 74 ± 14 years. At least one comorbid disease was present in 94% of the cases, and hypertension was the most common. When ICU weight scores were examined, Acute Physiology and Chronic Health Evaluation-II: 19 (15-27) and Sequential Organ Failure Assessment: 7 (4-10) were seen. Sepsis was present in 37% (n = 298) of cases. $\text{PaO}_2/\text{FiO}_2$ ratios of the patients were 190 the highest and 150 the lowest and 51% of the cases were followed via invasive mechanical ventilation. On the study day, 73% bilateral involvement was seen on chest x-ray, and ground-glass opacities (52%) were the most common on chest tomography. There was growth in culture in 40% (n = 318) of the cases, and the most common growth was in the tracheal aspirate (42%).

CONCLUSION: The clinical course of COVID-19 is variable, and ICU follow-up was required due to advanced age, comorbidity, presence of respiratory symptoms, and widespread radiological involvement. The need for respiratory support and the presence of secondary infection are important issues to be considered in the follow-up. Despite the end of the second year of the pandemic and vaccination, the high severity of the disease as well as the need for follow-up in ICUs has shown that COVID-19 is an important health problem.

KEYWORDS: COVID-19, intensive care, intensive care unit, pandemic, follow-up

Received: March 17, 2023

Accepted: September 12, 2023

Publication Date: November 20, 2023

INTRODUCTION

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first described in December 2019 in China and rapidly spread to other countries.¹ As of March 11, 2022, nearly 602 million confirmed COVID-19 cases have been reported globally; of these cases, 576 million recovered

from the disease, and 6 million people died.² Coronavirus disease 2019 presents with a wide clinical spectrum ranging from asymptomatic illness to respiratory failure, and patients were followed up in the intensive care unit (ICU) for different causes such as severe pneumonia, sepsis, and acute respiratory distress syndrome (ARDS). Epidemiological and clinicopathological features of disease were evaluated worldwide. Reportedly, COVID-19

cases include 14% of severe illnesses and 6% of critical illnesses that required intensive care; 2% of these cases underwent invasive mechanical ventilation (IMV).³ The ICU mortality rate ranges from 4 to 11%.^{4,5} In Turkey, the data about ICU follow-up are limited. This study aimed to describe demographical and clinical characteristics, ventilation settings, treatment regimens, and outcomes in patients with COVID-19 who were followed up in ICUs. Thus, to obtain data on different ICUs in our country in the second year of the pandemic, a 1-day point prevalence study was planned via the Turkish Thoracic Society (TTS) Respiratory Failure and Intensive Care Association.

MATERIAL AND METHODS

This descriptive cross-sectional research was designed as a 1-day point prevalence study. The study was announced to the members practicing in the ICUs via mail through the societies (TTS and the Turkish Society of Intensive Care). Consent forms were shared with the centers that participated in the study. All cases of initial real-time polymerase chain reaction (RT-PCR)-positive cases hospitalized in the ICUs due to COVID-19 between March 11, 2022, 8:00 AM, and March 12, 2022, 8:00 AM, were included. The data were collected via e-mail from each center. The study was approved by the ethical committee of Health Sciences University İzmir Dr. Suat Seren Chest Disease and Thoracic Surgery Training and Research Hospital (March 10, 2022/10-14) and was in accordance with the Declaration of Helsinki.

Patients

According to the COVID-19 guidelines of the Ministry of Health, patients in ICUs should be followed up based on the following conditions:⁶

- Dyspnea and respiratory distress.
- Respiratory rate ≥ 30 /min.
- $\text{PaO}_2/\text{FiO}_2$ ratio < 300 .
- Increased oxygen recruitment.
- $\text{SaO}_2 < 90\%$ or $\text{PaO}_2 < 70$ mm Hg despite 5 L/min oxygen therapy.
- Hypotension (systolic blood pressure < 90 mm Hg and more than 40 mm Hg decrease from usual systolic blood pressure and mean arterial pressure < 65 mm Hg), tachycardia > 100 /min.

Main Points

- Coronavirus disease 2019 (COVID-19) patients were followed up in intensive care units for different causes, such as severe pneumonia, sepsis, and acute respiratory distress syndrome.
- The clinical features of the COVID-19 patients in the intensive care unit (ICU) during the second year of the pandemic were as follows: majority of the patients were over 65 years old and had comorbid diseases, ICU severity scores were high, and $\text{PaO}_2/\text{FiO}_2$ ratios were in lower limits.
- The clinical course of COVID-19 is variable, and ICU follow-up is required due to advanced age, comorbidity, the presence of respiratory symptoms, and radiological extensive involvement.

- Development of acute organ dysfunction such as acute kidney injury, impaired acute liver function tests, confusion, and acute bleeding diathesis.
- Patients with immunosuppression.
- Increased troponin levels and arrhythmia.
- Lactate > 2 mmol.
- Presence of capillary return disorder and cutis marmorata.

Assessments

Data on case demographics (age and gender), COVID-19 PCR results, comorbidities, symptoms, ICU duration, chest x-ray and computed tomography (CT) features, Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, $\text{PaO}_2/\text{FiO}_2$ ratio, type of respiratory support therapy (nasal oxygen, mask oxygen, high flow oxygen, noninvasive ventilation [NIV], IMV), accompanying conditions (sepsis, septic shock, ARDS), complete blood count and CRP, types of medical treatment (antibiotics, corticosteroids, anticytokine), and follow-up results were obtained at study day.

Clinical suspicion of infection and an increase in inflammatory markers that were consistent with culture positivity (tracheal aspirate, blood, urine, and wound samples) were defined as non-COVID-19 secondary infections.

Statistical Analysis

The statistical analysis was performed using Statistical Package for the Social Sciences Statistics software for Windows, version 21.0 (IBM Corp., Armonk, NY, USA). Descriptive analyses were done for the patients' demographics and clinical data. Student's *t*-test was performed for continuous variables with normally distributed values, and the values were defined as the mean \pm standard deviation (SD). The Mann-Whitney *U*-test was used for non-normally distributed continuous values, and the results were shown as median and 25%-75% as interquartile ratio (IQR). Counts and percentages were used when applicable.

RESULTS

A total of 811 cases from 59 centers were included in the study. Table 1 shows the demographic characteristics and radiologic features of patients on study day. Four hundred eighty-two (59%) of the cases were male, and the median age was 74 years. Nearly all of the cases had at least 1 comorbidity; hypertension (57%), diabetes mellitus (31%), coronary artery disease (26%), and chronic obstructive pulmonary disease (COPD) (20%), were the most frequent comorbidities. Of the cases, 73% were vaccinated for COVID-19, and on study day, 77% of the cases COVID PCR tests were positive. Of the patients, 780 (96%) had symptoms of COVID-19 at ICU admission, and dyspnea was the most common symptom. The laboratory data of the cases followed up in ICUs in the second year of the pandemic are shown in Table 1. Although most of the cases had bilateral involvement on the chest x-ray, the most common finding on the thorax CT was ground-glass opacities.

The ICU data and type of respiratory support of the cases followed up in the ICUs in the second year of the pandemic

Table 1. Demographic Characteristics and Initial Symptoms of Cases Followed in the Intensive Care Units (n = 811)

Age, year, mean \pm SD	74 \pm 14
Male, n (%)	482 (59)
Comorbidity, n (%)	763 (94)
COPD	164 (20)
HT	462 (57)
CVD	214 (26)
AF	109 (13)
CHF	161 (20)
DM	252 (31)
Alzheimer's	145 (18)
CVD	116 (14)
Malignancy	122 (15)
COVID vaccine, n (%)	591 (73)
Last COVID-19 PCR result, positive; n (%)	619 (77)
Presence of symptoms at admission, n (%)	780 (96)
Fever	161 (20)
Cough	362 (45)
Dyspnea	692 (85)
Leucocyte count, 10 ⁹ L, median (25-75)	10205 (7100-14700)
Lymphocyte count, median (25-75)	710 (400-1150)
CRP (mg/dL), median (25-75)	108 (48-171)
Involvement on chest x-ray, n (%)	
Unilateral	161 (20)
Bilateral	590 (73)
Lesion on thorax CT, n (%)	
Ground-glass opacity	394 (52)
Consolidation	180 (24)
Fibrosis	19 (3)

AF, atrial fibrillation; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; HT, hypertension; PCR, polymerase chain reaction.

are shown in Table 2. On ICU admission, the APACHE-II and SOFA scores were 19 (15-27) and 5 (4-10), respectively. On study day, half of the cases were intubated and followed up with IMV for a median of 8 days, and 298 (37%) of cases had sepsis. Extracorporeal membrane oxygenation (ECMO) was applied to 1 of 811 patients, and 8 of the cases were in a prone position on the study day. Culture positivity was observed in 40% (318) of the cases; the most common positivity was detected in the tracheal aspirate specimen (42%), and *Acinetobacter baumannii* was identified frequently. On study day, 89 (11%) patients died in ICUs, 28 (4%) were discharged, and 693 (86%) were still in ICUs Table 2 shows the treatment procedures, infection status, and outcomes of the cases followed up in ICUs.

Table 2. Intensive Care Unit Data, Treatments and Outcomes of the Cases Followed in the Intensive Care Unit in the Second Year of the Pandemic (n = 811)

ICU duration, day, median (25-75)	9 (3-16)
APACHE II score, median (25-75)	19 (15-27)
SOFA score, median (25-75)	7 (4-10)
Lowest PaO ₂ /FiO ₂ , median (25-75)	150 (100-220)
Respiratory support therapies, n (%)	
Room air	12 (1)
Nasal O ₂	109 (13)
Mask O ₂	38 (5)
Reservoir oxygen mask	62 (8)
HFO	105 (13)
NIMV	70 (9)
IMV	415 (51)
HFO (day), median (25-75)	3 (2-6)
NIV (day), median (25-75)	2 (2-5)
IMV (day), median (25-75)	8 (3-18)
Tracheostomy, n (%)	63 (8)
Tracheostomy (day), median (25-75)	12 (6-21)
Sepsis, n (%)	298 (37)
Dialysis, n (%)	68 (8)
ECMO, n (%)	1 (0.1)
Prone position, n (%)	65 (8)
Anticytokine therapy (anakinra), n (%)	17 (2)
Pulse/mini pulse corticosteroid, n (%)	163 (20)
Anticoagulant, n (%)	753 (92)
Vasopressor, n (%)	283 (35)
Antibiotic therapy, n (%)	653 (82)
Antibiotic duration, median (25-75)	5 (3-9)
Culture positivity, n (%)	318 (40)
Source of infection, n (%)	
Tracheal aspirate	139 (42)
Blood	128 (38)
Urine	62 (19)
Wound	4 (1)
Pathogen, n (%)	
<i>Acinetobacter baumannii</i>	84 (10)
<i>Klebsiella pneumoniae</i>	50 (6)
<i>Candida</i> spp.	39 (5)
<i>Pseudomonas aeruginosa</i>	15 (2)
Result, n (%)	
Exitus	89 (11)
Discharge from ICU	28 (4)
Continued ICU stay	693 (86)

APACHE, acute physiology and chronic health evaluation; ECMO, extracorporeal membrane oxygenation; HFO, high-flow oxygen; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, noninvasive ventilation; PaO₂/FiO₂, arterial oxygen tension/fraction of inspired oxygen; SOFA, sequential organ failure assessment.

DISCUSSION

The present study evaluated the clinical features of patients with COVID-19 in various ICUs during the second year of the pandemic. Most of the patients were over 65 years old and had comorbid diseases; their ICU severity scores were high, and PaO₂/FiO₂ ratios were in lower limits. The clinical course of COVID-19 is variable, and ICU follow-up is required owing to advanced age, comorbidity, the presence of respiratory symptoms, and extensive radiological involvement.

As reported in the ICU data of different countries, the cases followed up in ICUs due to severe COVID-19 were 60%-80% male, and the mean age was 60-70 years.^{3,7,8} Consistent with these data, most of the patients hospitalized in the ICUs in our country were male and of elderly age. In a meta-analysis of 8 studies that involved 1816 patients, COPD, cardiovascular disease, and hypertension were found to be risk factors for severe illnesses and ICU admission.⁹ Similarly, a prospective, multicentre cohort study, from 63 ICUs enrolled patients over 18 years old with RT-PCR-confirmed COVID-19 who were on IMV and showed hypertension and obesity as the main comorbidities.¹⁰ Jain and Yuan⁹ reported that the most prevalent symptoms of severe COVID-19 were cough, fever, and fatigue. Moreover, cough, fever, and dyspnea were common in ICU patients. Dyspnea was found to be the only symptom that is associated with both severe disease and ICU admission. Similarly, in our study, dyspnea was observed in most patients during ICU admission.

Chau et al's¹¹ study in 2004 showed the relationship between the initial chest radiograph and the clinical outcome of patients with severe acute respiratory syndrome (SARS). Their results showed that bilateral disease and involvement of more than 2 zones on the chest radiograph were associated with poor clinical outcomes. Patients with bilateral involvement had a higher rate of ICU admission, assisted ventilation, and mortality in comparison with those with unilateral involvement. Similarly, bilateral involvement in chest x-ray has been reported to be more common in patients in ICUs.^{3,12,13} In our population, bilateral involvement in chest x-rays was detected frequently. Moreover, typical thorax CT features of COVID-19 were clearly defined as ground-glass opacities, with or without consolidations, in peripheral lung regions, and multifocal bilateral distribution. In most of the studies, such as ours, the common CT finding in ICU patients was ground-glass opacities.^{13,14}

Based on the intensive care data from different countries, IMV support ranged from 28%-100%.^{3,7,8,12,13,15} Patients included in our study were severe cases and half of them required IMV; thus, the APACHE II and SOFA scores of the present study were higher than the other studies.^{3,8,13,16} This may be due to the clinical characteristics of the patients admitted to the ICUs and the differences in ICU capacities in various countries. Additionally, the lower rates of PaO₂/FiO₂ ratio also led to IMV support. A lower PaO₂/FiO₂ ratio at ICU admission was reported as an independent risk factor for mortality.⁷ In previous studies, the use of NIV was reported to be 2%-11%, and the rate was similar in our data.^{3,7,8,13} This might be related to the prevalent application of NIV in the ward and intermediate ICU.

The data about bacterial and fungal coinfection in patients with COVID-19 show that their number is increasing over time, and coinfections were associated with a high mortality rate and a longer course of ICU stay. Bardi et al¹⁷ evaluated the epidemiological, clinical, and microbiological features and outcomes of ICU-acquired infections in their study which included 140 patients. The COVID-19-related nosocomial infection during ICU stay was defined as 41%. Furthermore, the nosocomial infections tended to be late complications occurring after 7 days of ICU stay.¹⁷ Nosocomial infections in ICU patients vary across a wide spectrum comprising such as ventilator-associated pneumonia, tracheobronchitis, catheter-related bloodstream infections, and urinary tract infections. In the present study, the most common microbiological isolates were *A. baumannii* and *Klebsiella pneumoniae*. Previous studies showed that immunomodulatory therapies, including tocilizumab and glucocorticoids, were associated with coinfections in patients with COVID-19.^{18,19} Moreover, higher APACHE II score at ICU admission was associated with infection.¹⁷ Interestingly, in our study, the rate of patients using antibiotics was higher than that of patients with culture positivity, i.e., 82% and 40%, respectively. This might be associated with the increased tendency to initiate empirical antibiotics by clinicians in ICUs.

Previous studies reported different ICU mortalities as follows: 16%-31%.^{7,13,16} A multicenter retrospective study reported COVID-19 mortality rate of 4.5% in our country. This study defined that male patients with severe pneumonia, multi-organ dysfunction, malignancy, sepsis, and interstitial lung diseases were at increased risk of mortality.²⁰ The mortality rate was twice as high as in the present study, which might be related to the fact that our study included only patients in ICUs.

This study has some limitations. First, it is a cross-sectional 1-day point prevalence study and only shows the results on study day. It does not give information on the changing conditions in the follow-up of the patients. However, the results may be interpreted as a representation of severe COVID-19 and ICUs. Second, due to the multicenter nature of the study, the data may be heterogeneous due to the different structures of ICUs. However, considering that 59 different centers were evaluated, the results can provide important data on the ICUs in the whole country. To the best of our knowledge, this is the first and most widespread study that evaluates ICU patients with COVID-19.

CONCLUSION

In conclusion, this multicenter study showed that in the second year of the pandemic, the majority of the patients in ICUs were of elderly age and had comorbid diseases, high ICU severity scores, and high intubation rates. The clinical course of COVID-19 is variable, and ICU follow-up is required because of advanced age, comorbidity, the presence of respiratory symptoms, and extensive radiological involvement. Despite the end of the second year of the pandemic and vaccination, the severity of the disease is high enough to require follow-up in ICUs, which shows that COVID-19 continues to be an important health problem.

Ethics Committee Approval: The study was approved by the ethical committee of Health Sciences University Izmir Dr. Suat Seren Chest Disease and Thoracic Surgery Training and Research Hospital (Approval No:10-14 Date: 10.03.2022).

Informed Consent: Verbal informed consent was obtained from the patients who agreed to take part in the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – S.G., Ö.E.; Design – Ö.E., Ö.Y.M.; Supervision – N.A., E.T.; Resources – İ.G.E.İ., B.E.; Materials – S.G., E.T.; Data collection and/or Preprocessing – S.T., B.D.K., N.M.M., D.K., Ş.G.B., E.U., F.S., G.A., D.E., N.H.S., P.Ö., Z.Ö., M.O., C.Y.Ö., R.Y., D.Ö.B., H.C., B.G., C.C., M.G., H.İ., İ.S., F.Ö.S., E.M.A., H.D., S.F.Ö., Ü.K., S.Ö., M.B., D.F.E., U.S.K., L.A.D., E.T., K.A., T.A., H.Y., G.Z., V.Y., G.K., M.D., E.Ö., B.E., S.E., Y.Ş., B.Y., A.B., A.S., M.G., F.K., O.Ö.A., E.K., Ü.K., D.S.A., S.S., N.Ş., H.A., A.C.Y., N.K.Ö., Ç.A.U., M.B., S.S., H.K.Ö., K.U., İ.Y., M.C.A., İ.D., S.U.K., E.S.Ö., K.A., G.E.D., G.A., A.E., B.S.A., M.E.T., P.K., Y.A., B.Ç.G., Ö.Y.E., A.T., T.B., S.U., N.K., H.U.P., N.K.K., H.G., P.A., A.B.Ö., A.E., U.K., Ç.B., H.A., S.M., H.M., O.P.Z.M., H.Y., E.T.; Analysis and/or interpretation – Z.K., S.G.; Literature Search – Ö.Y.M., B.E.; Writing – S.G., Ö.E., E.T.; Critical Review – S.G., Ö.E., N.A.

Declaration of Interests: The authors have no conflict of interest to declare.

Funding: This study received no funding.

This article was presented as an oral presentation at the 25th Annual Congress of the Turkish Thoracic Society.

REFERENCES

- Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. *J Chin Med Assoc.* 2020;83(3):217-220. [\[CrossRef\]](#)
- Worldometer. COVID live–coronavirus statistics [online]. Available at: <https://www.worldometers.info/coronavirus/>. Accessed 23 August 2022.
- Sai F, Liu X, Li L, et al. Clinical characteristics and risk factors for mortality in patients with coronavirus disease 2019 in intensive care unit: a single-center, retrospective, observational study in China. *Ann Palliat Med.* 2021;10(3):2859-2868. [\[CrossRef\]](#)
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus Infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-1069. [\[CrossRef\]](#)
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507-513. [\[CrossRef\]](#)
- Sağlık Bakanlığı, COVID-19 Erişkin Hasta Tedavisi. Available at: <https://covid19.saglik.gov.tr/Eklenti/43095/0/covid-19rehber-iriskinhastayonetimivedavisi-12042022pdf.pdf>
- Grasselli G, Greco M, Zanella A, et al. COVID-19 Lombardy ICU network. Risk Factors Associated With mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Internmed.* 2020;180(10):1345-1355. [\[CrossRef\]](#) Erratum in: *JAMA Internmed.* 2021;181(7):1021.
- Ñamendys-Silva SA, Alvarado-Ávila PE, Domínguez-Cherit G, et al. Mexico COVID-19 critical care collaborative group. Outcomes of patients with COVID-19 in the intensive care unit in Mexico: a multicenter observational study. *Heart Lung.* 2021;50(1):28-32. [\[CrossRef\]](#)
- Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. *Int J Public Health.* 2020;65(5):533-546. [\[CrossRef\]](#)
- Estenssoro E, Loudet CI, Ríos FG, et al. SATI-COVID-19 study group. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicenter cohort study. *Lancet Respir Med.* 2021;9(9):989-998. [\[CrossRef\]](#)
- Chau TN, Lee PO, Choi KW, et al. Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome. *Am J Med.* 2004;117(4):249-254. [\[CrossRef\]](#)
- Aleva FE, van Mourik L, Broeders MEAC, Paling AJ, de Jager CPC. COVID-19 in critically ill patients in North Brabant, the Netherlands: patient characteristics and outcomes. *J Crit Care.* 2020;60:111-115. [\[CrossRef\]](#)
- Ito J, Seo R, Kawakami D, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: a single-center, retrospective, observational study. *J Anesth.* 2021;35(2):213-221. [\[CrossRef\]](#)
- Negróni D, Zagaria D, Paladini A, et al. COVID-19 CT scan lung segmentation: how we do it. *J Digit Imaging.* 2022;35(3):424-431. [\[CrossRef\]](#)
- Prokop M, van Everdingen W, van Rees Vellinga T, et al. COVID-19 Standardized Reporting Working group of the Dutch Radiological Society. CO-RADS: a categorical CT Assessment Scheme for patients suspected of having COVID-19-definition and evaluation. *Radiology.* 2020;296(2):E97-E104. [\[CrossRef\]](#)
- Torres A, Motos A, Ceccato A, et al. Methodology of a large Multicenter Observational study of patients with COVID-19 in Spanish intensive care units. *Arch Bronconeumol.* 2022;58(suppl 1):22-31. [\[CrossRef\]](#)
- Bardi T, Pintado V, Gomez-Rojo M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. *Eur J Clin Microbiol Infect Dis.* 2021;40(3):495-502. [\[CrossRef\]](#)
- Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol.* 2021;2(8):e474-e484. [\[CrossRef\]](#)
- Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med.* 2021;384(8):693-704. [\[CrossRef\]](#)
- Kokturk N, Babayigit C, Kul S, et al. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. *Respir Med.* 2021;183:106433. [\[CrossRef\]](#)